France· FR:62719472
SIALANAR 320 microgrammes/ml, solution buvable
A glycopyrronium product containing bromure de glycopyrronium, registered in France by PROVECA PHARMA LIMITED (IRLANDE), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Glycopyrronium is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AA01 (glycopyrronium), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Glycopyrronium · ATC D11AA01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BROMURE DE GLYCOPYRRONIUM
- Manufacturer
- PROVECA PHARMA LIMITED (IRLANDE)
- Country
- France (FR)
- ATC code
- D11AA01
- ATC class
- Glycopyrronium
- Defined daily dose
- 8.8 mg, T
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009301460191 flacon en verre ambré de 250 mL avec fermeture de sécurité enfant avec seringue pour administration orale polyéthylène basse densité (PEBD) de 8 mL et adaptateurEUR 422.19
- cip1334009302780621 flacon en verre ambré de 60 mL avec fermeture de sécurité enfant avec seringue pour administration orale polyéthylène basse densité (PEBD) de 8 mL et adaptateurEUR 101.91
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
108 interactions on record for glycopyrronium.
Graded by severity as the source publishes them — 107 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glycopyrronium · interactions on record
108 records
- 107 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under D11AA01
Glycopyrronium, as other registers publish it.
- United KingdomAssicco 1mg tabletsMorningside Healthcare Ltd
- United KingdomAssicco 2mg tabletsMorningside Healthcare Ltd
- BelgiumAxhidroks 8 mg/gDr. Wolff Arzneimittel
- FinlandAxhidroxDr. August Wolff GmbH & Co. KG Arzneimittel
- NorwayAxhidroxDr. August Wolff GmbH & Co. Arzneimittel
- PolandAxhidroxDr. August Wolff GmbH & Co. KG Arzneimittel
- GermanyAxhidroxDr. August Wolff Gmbh & Co. Kg Arzneimittel
- DenmarkAxhidroxDr. August Wolff GmbH & Co. KG Arzneimittel
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f9436385-7f4f-4da2-9f10-49dcc536cdf4 GET /v1/drugs/f9436385-7f4f-4da2-9f10-49dcc536cdf4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62719472",
"date_amm": "2016-09-15",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/16/1135",
"substance": "BROMURE DE GLYCOPYRRONIUM",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution buvable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about glycopyrronium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.